Kiora Pharmaceuticals Announces Board and Executive Changes
Ticker: KPHMW · Form: 8-K · Filed: Jan 15, 2025 · CIK: 1372514
| Field | Detail |
|---|---|
| Company | Kiora Pharmaceuticals Inc (KPHMW) |
| Form Type | 8-K |
| Filed Date | Jan 15, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.01, $443,000.04, $30,000, $337,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
Related Tickers: KPRX
TL;DR
Kiora Pharma shakes up board & exec pay. Big changes coming?
AI Summary
Kiora Pharmaceuticals, Inc. announced on January 10, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for key personnel.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, leadership, and financial priorities, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty about future strategy and execution.
Key Numbers
- 001-36672 — SEC File Number (Identifies the company's filing with the SEC.)
- 20250110 — Report Date (The earliest event date reported in this 8-K filing.)
Key Players & Entities
- KIORA PHARMACEUTICALS, INC. (company) — Registrant
- EYEGATE PHARMACEUTICALS INC (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
FAQ
Who departed from Kiora Pharmaceuticals' board or officer positions?
The filing indicates the departure of certain officers and directors, though specific names are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on January 10, 2025.
What is Kiora Pharmaceuticals' state of incorporation?
Kiora Pharmaceuticals, Inc. is incorporated in Delaware.
What is the company's former name?
The company's former name was EYEGATE PHARMACEUTICALS INC.
What are the main items covered in this 8-K filing?
This 8-K filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.
Filing Stats: 1,189 words · 5 min read · ~4 pages · Grade level 12 · Accepted 2025-01-15 17:22:54
Key Financial Figures
- $0.01 — nge on which registered: Common Stock, $0.01 par value KPRX NASDAQ Indicate by che
- $443,000.04 — s will receive an annual base salary of $443,000.04 and he is entitled to receive a perform
- $30,000 — erannuation contributions (capped at AUD$30,000 annually) as previously provided to Dr.
- $337,000 — a will receive an annual base salary of $337,000 and she is entitled to receive a perfor
Filing Documents
- kprx-20250110.htm (8-K) — 34KB
- exhibit-101.htm (EX-10.1) — 69KB
- exhibit-102.htm (EX-10.2) — 64KB
- 0001372514-25-000003.txt ( ) — 325KB
- kprx-20250110.xsd (EX-101.SCH) — 2KB
- kprx-20250110_lab.xml (EX-101.LAB) — 22KB
- kprx-20250110_pre.xml (EX-101.PRE) — 13KB
- kprx-20250110_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Title 10.1 1 Employment Agreement by and between Kiora Pharmaceuticals , Inc. and Eric J. Daniels, date d as of January 10 , 2025 10.2 1 Employment Agreement by and between Kiora Pharmaceuticals, Inc. and Melissa Tosca , dated as of January 10 , 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 Management contract or compensatory plan or arrangement.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KIORA PHARMACEUTICALS, INC. By: /s/ Melissa Tosca Melissa Tosca Chief Financial Officer (Principal financial and accounting officer) Date: January 15, 2025